Life Expectancy After Failed Autologous Transplant in Follicular Lymphoma

Survival Outcomes After Failed Autologous Transplant

Patients with follicular lymphoma who relapse after autologous stem cell transplantation have poor outcomes with conventional therapies alone, according to the American Journal of Hematology 1
The European Bone Marrow Transplant Group reported that with allogeneic transplantation using reduced-intensity conditioning, the 4-year overall survival rate was 76% in patients with follicular lymphoma, with non-relapse mortality approximately 15% at 4 years, and risk of relapse around 26% 1

For patients who are not candidates for allogeneic transplantation, novel therapeutic approaches including targeted agents and immunotherapies should be considered, as recommended by the Journal of the National Cancer Institute 2
Reduced-intensity conditioning regimens have shown similar efficacy to myeloablative conditioning with potentially lower treatment-related mortality in appropriate candidates, according to the American Journal of Hematology 1

The natural history of follicular lymphoma has improved significantly over recent decades, with median overall survival increasing from 6.7 years in the 1990s to exceeding 18 years in the current treatment era, as reported by the Journal of the National Cancer Institute 2, 3

Allogeneic stem cell transplantation offers a potential cure rate of 76-85% at 4-8 years in patients with follicular lymphoma, though it carries significant treatment-related mortality risks of 15-20% 4
Most studies show survival curves reaching a plateau at 12-24 months post-transplantation, suggesting curative potential 5
Non-relapse mortality is approximately 15% at 4 years, with higher rates in unrelated donor transplants compared to sibling donor transplants 4

The American Society of Hematology recommends allogeneic stem cell transplantation for young, fit patients who have relapsed after or are refractory to previous therapies, including autologous stem cell transplantation 4, 6

For patients who relapse after autologous stem cell transplantation, allogeneic stem cell transplantation offers the only potential curative approach 4, 7

Transplant-related mortality increases significantly in patients over 50 years, even with reduced-intensity conditioning 5